{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:19:34Z","timestamp":1787552374103,"version":"build-2736575974"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>\n                    Inherited genodermatoses are a heterogeneous group of rare monogenic disorders. Among these, epidermolysis bullosa (EB) and ichthyoses represent paradigmatic disorders characterized by severe skin fragility and hyperkeratosis, respectively, and impaired barrier function, often with profound effects on quality of life and systemic health. Current management remains largely palliative, underscoring the urgent need for disease-modifying therapies. Over the past 2\u00a0decades, advances in epithelial stem cell biology, vector engineering and genome editing technologies have transformed the therapeutic landscape for genodermatoses.\n                    <jats:italic>Ex vivo<\/jats:italic>\n                    gene therapy has provided the first proof that genetically corrected epidermal stem cells can achieve long-term tissue regeneration in EB skin patients, establishing a new paradigm for regenerative medicine. In parallel, the emergence of programmable genome engineering platforms, including CRISPR\/Cas nucleases, base editors and prime editors, have enabled increasingly precise strategies for mutation-specific correction in both recessive and dominant disorders. Furthermore, the development of\n                    <jats:italic>in vivo<\/jats:italic>\n                    topical approaches is expanding the possibility of directly targeting the skin. Despite these advances, substantial translational barriers continue to limit broad clinical implementation. Efficient and durable targeting of epidermal stem cells within a highly regenerative tissue, together with safe delivery across the skin barrier, stringent control of off-target activity, scalable manufacturing and demonstration of long-term safety, remain major challenges for the clinical translation of these approaches. In this Review, we discuss the current state of gene therapy for genodermatoses, highlighting key clinical milestones, emerging genome editing technologies and next-generation delivery systems. We further examine the biological and regulatory challenges that need to be overcome to bridge the gap between experimental innovation and clinically accessible therapies for patients with inherited skin diseases.\n                  <\/jats:p>","DOI":"10.3389\/fbioe.2026.1901459","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:31:10Z","timestamp":1787549470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene therapy for genodermatoses at the crossroads of innovation and clinical translation"],"prefix":"10.3389","volume":"14","author":[{"given":"Alessandra","family":"Fabrizi","sequence":"first","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valenti","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zacchino","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Russo","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Baschetti","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Luca","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cStefano Ferrari\u201d Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1600-0625.2007.00691.x","article-title":"An update on molecular aspects of the non-syndromic ichthyoses","volume":"17","author":"Akiyama","year":"2008","journal-title":"Exp. Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1172\/JCI24834","article-title":"Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer","volume":"115","author":"Akiyama","year":"2005","journal-title":"J. Clin. Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/bjd\/ljaf154","article-title":"Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy","volume":"193","author":"Akiyama","year":"2025","journal-title":"Br. J. Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/humu.21551","article-title":"The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations","volume":"32","author":"van den Akker","year":"2011","journal-title":"Hum. Mutat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1093\/bioinformatics\/btac697","article-title":"CRISPRon\/off: CRISPR\/Cas9 on- and off-target gRNA design","volume":"38","author":"Anthon","year":"2022","journal-title":"Bioinformatics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2026.01.001","article-title":"Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin models","volume":"33","author":"Apaydin","year":"2026","journal-title":"Cell Stem Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/jid.2011.169","article-title":"Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex","volume":"131","author":"Atkinson","year":"2011","journal-title":"J. Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ajhg.2013.08.003","article-title":"Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts","volume":"93","author":"Aufenvenne","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.omtm.2017.06.008","article-title":"Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis Bullosa simplex patients","volume":"6","author":"Aushev","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae","year":"2014","journal-title":"Bioinformatics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat. Rev. Dis. Primer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ymthe.2025.11.023","article-title":"Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosa","volume":"34","author":"Bassons-Bascu\u00f1ana","year":"2026","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","article-title":"Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells","volume":"137","author":"Bauer","year":"2017","journal-title":"J. Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1089\/crispr.2021.0132","article-title":"Allele-specific inactivation of an autosomal dominant epidermolysis Bullosa simplex mutation using CRISPR-Cas9","volume":"5","author":"Bchetnia","year":"2022","journal-title":"CRISPR J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","article-title":"CRISPR\/Cas9-Mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis Bullosa patient","volume":"26","author":"Benati","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2217\/imt.11.2","article-title":"Immune recognition and rejection of allogeneic skin grafts","volume":"3","author":"Benichou","year":"2011","journal-title":"Immunotherapy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/wrna.1347","article-title":"mRNA trans-splicing in gene therapy for genetic diseases","volume":"7","author":"Berger","year":"2016","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jid.2023.10.035","article-title":"Highly efficient Ex Vivo correction of COL7A1 through ribonucleoprotein-based CRISPR\/Cas9 and homology-directed repair to treat recessive dystrophic epidermolysis bullosa","volume":"144","author":"Berthault","year":"2024","journal-title":"J. Invest Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.omtm.2017.10.002","article-title":"Analyzing the genotoxicity of retroviral vectors in hematopoietic cell gene therapy","volume":"8","author":"Biasco","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.ymthe.2022.04.020","article-title":"Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa","volume":"30","author":"Bischof","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/ijms25042243","article-title":"Emerging gene therapeutics for epidermolysis bullosa under development","volume":"25","author":"Bischof","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","article-title":"Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR\/Cas9-Mediated gene editing","volume":"27","author":"Bonafont","year":"2019","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.ymthe.2021.02.019","article-title":"Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing","volume":"29","author":"Bonafont","year":"2021","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","article-title":"QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study","volume":"141","author":"Bornert","year":"2021","journal-title":"J. Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1038\/mtna.2016.87","article-title":"Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa","volume":"5","author":"Bremer","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3390\/ijms24032298","article-title":"Challenges of gene editing therapies for genodermatoses","volume":"24","author":"Brooks","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"102719","DOI":"10.1016\/j.omtn.2025.102719","article-title":"Prime editing in mammals: from promise to practicalities","volume":"36","author":"Brooks","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jid.2022.05.303","article-title":"295 Collagen 7 (C7) protein replacement therapy (PTR-01) durably reduces wound size and symptoms in patients with recessive dystrophic epidermolysis bullosa (RDEB)","volume":"142","author":"Bruckner","year":"2022","journal-title":"J. Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jid.2019.03.456","article-title":"380 KB104: an HSV-based gene therapy vector engineered to deliver functional SPINK5 for the treatment of Netherton syndrome","volume":"139","author":"Bustos","year":"2019","journal-title":"J. Invest Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ymthe.2023.11.027","article-title":"Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells","volume":"32","author":"Cattaneo","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/MCB.15.4.1968","article-title":"Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae","volume":"15","author":"Choulika","year":"1995","journal-title":"Mol. Cell Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1089\/hum.1996.7.18-2247","article-title":"Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes","volume":"7","author":"Choate","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.molcel.2018.11.031","article-title":"Target-specific precision of CRISPR-mediated genome editing","volume":"73","author":"Chakrabarti","year":"2019","journal-title":"Mol. Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1038\/mtna.2016.19","article-title":"Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis Bullosa keratinocytes","volume":"5","author":"Chamorro","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(92)90314-3","article-title":"The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes","volume":"70","author":"Cheng","year":"1992","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0092-8674(92)90315-4","article-title":"A leucine----proline mutation in the H1 subdomain of keratin 1 causes epidermolytic hyperkeratosis","volume":"70","author":"Chipev","year":"1992","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3390\/ijms23052506","article-title":"Current strategies for the gene therapy of autosomal recessive congenital ichthyosis and other types of inherited ichthyosis","volume":"23","author":"Chulpanova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis Bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/s41587-024-02488-6","article-title":"Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations","volume":"43","author":"Cullot","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/toxsci\/kfw220","article-title":"Viral vectors: the road to reducing genotoxicity","volume":"155","author":"David","year":"2017","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.celrep.2019.04.055","article-title":"Laminin 332-Dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis Bullosa","volume":"27","author":"De","year":"2019","journal-title":"Cell Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1089\/hum.2019.049","article-title":"Generation and clinical application of gene-modified autologous epidermal sheets in Netherton syndrome: lessons learned from a phase 1 trial","volume":"30","author":"Di","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/00128071-200304020-00002","article-title":"Ichthyosis: etiology, diagnosis, and management","volume":"4","author":"DiGiovanna","year":"2003","journal-title":"Am. J. Clin. Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e130554","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1042\/BCJ20170793","article-title":"CRISPR base editors: genome editing without double-stranded breaks","volume":"475","author":"Eid","year":"2018","journal-title":"Biochem. J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.ymthe.2026.02.044","article-title":"Base-edited skin equivalents: a promising ex vivo approach for recessive dystrophic epidermolysis bullosa","volume":"34","author":"Fabrizi","year":"2026","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fmed.2017.00053","article-title":"Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe","volume":"4","author":"Farkas","year":"2017","journal-title":"Front. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","article-title":"Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry","volume":"152","author":"Fine","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","article-title":"The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB","volume":"58","author":"Fine","year":"2008","journal-title":"J. Am. Acad. Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J. Am. Acad. Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12939-025-02710-0","article-title":"Personalized medicine and health equity: overcoming cost barriers and ethical challenges","volume":"25","author":"Francisco","year":"2025","journal-title":"Int. J. Equity Health"},{"key":"B55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jid.2020.07.035","article-title":"Preclinical evaluation of a modified Herpes simplex virus type 1 vector encoding human TGM1 for the treatment of autosomal recessive congenital ichthyosis","volume":"141","author":"Freedman","year":"2021","journal-title":"J. Invest Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM198408163110706","article-title":"Permanent coverage of large burn wounds with autologous cultured human epithelium","volume":"311","author":"Gallico","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"102771","DOI":"10.1016\/j.omtn.2025.102771","article-title":"Research progress of base editing and prime editing tools based on the CRISPR\/Cas system","volume":"36","author":"Gao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.omtm.2022.09.005","article-title":"Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors","volume":"27","author":"Garc\u00eda","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/bjd.18559","article-title":"EBGene trial: patient preselection outcomes for the european GENEGRAFT ex vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa","volume":"182","author":"Gaucher","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"100005","DOI":"10.1016\/j.ggedit.2021.100005","article-title":"Base editors: expanding the types of DNA damage products harnessed for genome editing","volume":"1","author":"Gu","year":"2021","journal-title":"Gene Genome"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene Geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-022-00412-3","article-title":"Ichthyosis","volume":"9","author":"Guti\u00e9rrez-Cerrajero","year":"2023","journal-title":"Nat. Rev. Dis. Primer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.ymthe.2022.06.005","article-title":"Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa","volume":"30","author":"Hong","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1046\/j.1523-1747.2000.00942.x","article-title":"Efficient in vitro transfection of human keratinocytes with an adenovirus-enhanced receptor-mediated system","volume":"114","author":"Huber","year":"2000","journal-title":"J. Invest Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"102472","DOI":"10.1016\/j.omtn.2025.102472","article-title":"Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa","volume":"36","author":"Hunt","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B73","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex Vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B74","doi-asserted-by":"publisher","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B75","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B77","first-page":"390","article-title":"Anatomy, histology and immunohistochemistry of normal human skin","volume":"12","author":"Kanitakis","year":"2002","journal-title":"Eur. J. Dermatol EJD"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1086\/429844","article-title":"Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis","volume":"76","author":"Kelsell","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"B80","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1097\/MS9.0000000000001422","article-title":"Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa","volume":"85","author":"Khan","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"B81","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12015-024-10835-y","article-title":"Elevating dermatology beyond aesthetics: Perinatal-Derived advancements for rejuvenation, alopecia strategies, scar therapies, and progressive wound healing","volume":"21","author":"Khalilzad","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","article-title":"On- and off-target effects of paired CRISPR-Cas nickase in primary human cells","volume":"32","author":"Klermund","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ymthe.2017.08.015","article-title":"Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR\/Cas9 nickases","volume":"25","author":"Kocher","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.omtn.2019.09.011","article-title":"Improved double-nicking strategies for COL7A1-Editing by homologous recombination","volume":"18","author":"Kocher","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.jid.2020.02.012","article-title":"Predictable CRISPR\/Cas9-Mediated COL7A1 reframing for dystrophic epidermolysis bullosa","volume":"140","author":"Kocher","year":"2020","journal-title":"J. Invest Dermatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.omtn.2021.05.015","article-title":"A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa","volume":"25","author":"Kocher","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B88","doi-asserted-by":"publisher","first-page":"658295","DOI":"10.3389\/fgene.2021.658295","article-title":"Gene replacement therapies for genodermatoses: a status quo","volume":"12","author":"Koller","year":"2021","journal-title":"Front. Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2391452","DOI":"10.1080\/09546634.2024.2391452","article-title":"Emerging DNA and RNA editing strategies for the treatment of epidermolysis bullosa","volume":"35","author":"Koller","year":"2024","journal-title":"J. Dermatol Treat."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s13555-024-01239-4","article-title":"Highlights of gene and cell therapy for epidermolysis bullosa and ichthyosis","volume":"14","author":"Koutsoukos","year":"2024","journal-title":"Dermatol Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1056\/NEJMoa2108544","article-title":"Transgenic epidermal cultures for junctional epidermolysis bullosa - 5-year outcomes","volume":"385","author":"Kueckelhaus","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"W171","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","volume":"47","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.det.2009.10.013","article-title":"Kindler syndrome","volume":"28","author":"Lai-Cheong","year":"2010","journal-title":"Dermatol Clin."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40291-025-00804-7","article-title":"Prademagene zamikeracel: first approval","volume":"29","author":"Lee","year":"2025","journal-title":"Mol. Diagn Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s12276-025-01463-8","article-title":"Emerging trends in prime editing for precision genome editing","volume":"57","author":"Lee","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/ijms19030762","article-title":"RNA trans-splicing modulation via antisense molecule interference","volume":"19","author":"Liemberger","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for improving HDR efficiency","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Genet."},{"key":"B99","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.omtn.2018.05.005","article-title":"CRISPR\/Cas9-Mediated treatment ameliorates the phenotype of the epidermolytic Palmoplantar Keratoderma-like mouse","volume":"12","author":"Luan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B100","doi-asserted-by":"publisher","first-page":"EMBR202256661","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies","volume":"24","author":"De Luca","year":"2023","journal-title":"EMBO Rep."},{"key":"B101","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/17460751.1.1.45","article-title":"Regeneration of squamous epithelia from stem cells of cultured grafts","volume":"1","author":"De Luca","year":"2006","journal-title":"Regen. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","article-title":"Advances in stem cell research and therapeutic development","volume":"21","author":"De Luca","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"B103","article-title":"Dystrophic epidermolysis bullosa","volume-title":"Genereviews\u00ae","author":"Lucky","year":"1993"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.jid.2019.03.1146","article-title":"Gene editing-mediated disruption of epidermolytic ichthyosis-associated KRT10 alleles restores filament stability in keratinocytes","volume":"139","author":"March","year":"2019","journal-title":"J. Invest Dermatol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-025-00942-y","article-title":"Long-term safety and tolerability of beremagene Geperpavec-svdt (B-VEC) in an open-label extension study of patients with dystrophic epidermolysis bullosa","volume":"26","author":"Marinkovich","year":"","journal-title":"Am. J. Clin. Dermatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40257-025-00956-6","article-title":"Correction to: long-term safety and tolerability of beremagene Geperpavec-svdt (B-VEC) in an open-label extension study of patients with dystrophic epidermolysis bullosa","volume":"26","author":"Marinkovich","year":"","journal-title":"Am. J. Clin. Dermatol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"115359","DOI":"10.1016\/j.addr.2024.115359","article-title":"Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: clinical applications","volume":"211","author":"Masarwy","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.16882","article-title":"Management of congenital ichthyoses: european guidelines of care, part two","volume":"180","author":"Mazereeuw\u2010Hautier","year":"2019","journal-title":"Br. J. Dermatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.omtn.2018.01.009","article-title":"Deletion of a pathogenic mutation-containing exon of COL7A1 allows clonal gene editing correction of RDEB patient epidermal stem cells","volume":"11","author":"Menc\u00eda","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B112","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1590\/abd1806-4841.20132203","article-title":"Mosaic epidermolytic ichthyosis--case report","volume":"88","author":"Mendes","year":"2013","journal-title":"An Bras Dermatol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"106","DOI":"10.34763\/jmotherandchild.20252901.d-25-00014","article-title":"Netherton syndrome: a comprehensive literature review of pathogenesis, clinical manifestations, and therapeutic strategies","volume":"29","author":"Mocarska","year":"2025","journal-title":"J. Mother Child."},{"key":"B114","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J. Clin. Invest"},{"key":"B115","doi-asserted-by":"publisher","first-page":"746664","DOI":"10.3389\/fphar.2021.746664","article-title":"Challenges in treating genodermatoses: new therapies at the horizon","volume":"12","author":"Morren","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.28.529447","article-title":"A scalable, GMP-compatible, autologous organotypic cell therapy for dystrophic epidermolysis Bullosa","author":"Neumayer","year":"2023","journal-title":"bioRxiv Prepr. Serv. Biol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2009.11.020","article-title":"Revised nomenclature and classification of inherited ichthyoses: results of the first ichthyosis consensus conference in Sor\u00e8ze 2009","volume":"63","author":"Oji","year":"2010","journal-title":"J. Am. Acad. Dermatol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based gene correction for epidermolysis bullosa","volume":"21","author":"Osborn","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","article-title":"Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs","volume":"140","author":"Osborn","year":"2020","journal-title":"J. Invest Dermatol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41375-025-02585-8","article-title":"Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy","volume":"39","author":"Ottaviano","year":"2025","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jid.2018.08.027","article-title":"Profiling immune expression to consider repurposing therapeutics for the ichthyoses","volume":"139","author":"Paller","year":"2019","journal-title":"J. Invest Dermatol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/bjd\/ljaf123","article-title":"Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy","volume":"193","author":"Paller","year":"2025","journal-title":"Br. J. Dermatol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1021\/acs.biochem.9b00573","article-title":"Off-target editing by CRISPR-guided DNA base editors","volume":"58","author":"Park","year":"2019","journal-title":"Biochemistry"},{"key":"B124","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1038\/s41467-019-13620-5","article-title":"Author correction: gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat. Commun."},{"key":"B125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.17075","article-title":"An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex","volume":"180","author":"Peking","year":"2019","journal-title":"Br. J. Dermatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0140-6736(96)11188-0","article-title":"Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium","volume":"349","author":"Pellegrini","year":"1997","journal-title":"Lancet"},{"key":"B127","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/rme-2015-0051","article-title":"From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU","volume":"11","author":"Pellegrini","year":"2016","journal-title":"Regen. Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/sctm.17-0003","article-title":"Navigating market authorization: the path holoclar took to become the first stem cell product approved in the european union","volume":"7","author":"Pellegrini","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/jid.2012.11","article-title":"siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa","volume":"132","author":"Pendaries","year":"2012","journal-title":"J. Invest Dermatol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"976604","DOI":"10.3389\/fmed.2022.976604","article-title":"COL17A1 editing via homology-directed repair in junctional epidermolysis bullosa","volume":"9","author":"Petkovi\u0107","year":"2022","journal-title":"Front. Med."},{"key":"B131","article-title":"Junctional epidermolysis bullosa","volume-title":"Genereviews\u00ae","author":"Pfendner","year":"1993"},{"key":"B132","doi-asserted-by":"publisher","first-page":"115294","DOI":"10.1016\/j.addr.2024.115294","article-title":"Challenges and progress related to gene editing in rare skin diseases","volume":"208","author":"Pi\u00f1\u00f3n Hofbauer","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jid.2018.11.002","article-title":"Transglutaminase 1 replacement therapy successfully mitigates the autosomal recessive congenital ichthyosis phenotype in full-thickness skin disease equivalents","volume":"139","author":"Plank","year":"2019","journal-title":"J. Invest Dermatol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/exd.13979","article-title":"Epidermolysis bullosa: advances in research and treatment","volume":"28","author":"Prodinger","year":"2019","journal-title":"Exp. Dermatol"},{"key":"B135","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3272052392","article-title":"Generalized epidermolytic ichthyosis with palmoplantar hyperkeratosis","volume":"27","author":"Putra","year":"2021","journal-title":"Dermatol Online J."},{"key":"B136","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1038\/s41467-020-17626-2","article-title":"Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich syndrome","volume":"11","author":"Rai","year":"2020","journal-title":"Nat. Commun."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e10640","DOI":"10.1002\/btm2.10640","article-title":"Highly efficient CRISPR\/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa","volume":"9","author":"du Rand","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.xjidi.2024.100343","article-title":"Efficient dual Cas9 nickase correction of a prevalent pathogenic LAMB 3 variant for junctional epidermolysis Bullosa","volume":"5","author":"du Rand","year":"2025","journal-title":"JID Innov. Skin. Sci. Mol. Popul. Health"},{"key":"B140","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40265-026-02285-2","article-title":"Developing CRISPR-based therapies for epidermolysis bullosa: a comprehensive review of current strategies","volume":"86","author":"Du Rand","year":"2026","journal-title":"Drugs"},{"key":"B141","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clindermatol.2004.07.022","article-title":"Immunology of skin transplantation","volume":"23","author":"Richters","year":"2005","journal-title":"Clin. Dermatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"adv00523","DOI":"10.2340\/00015555-3875","article-title":"Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study","volume":"101","author":"Robertson","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.adengl.2011.11.021","article-title":"Autosomal recessive congenital ichthyosis","volume":"104","author":"Rodr\u00edguez-Pazos","year":"2013","journal-title":"Actas Dermosifiliogr."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.stemcr.2013.11.001","article-title":"Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa","volume":"2","author":"De Rosa","year":"2014","journal-title":"Stem Cell Rep."},{"key":"B146","doi-asserted-by":"publisher","first-page":"a035667","DOI":"10.1101\/cshperspect.a035667","article-title":"Toward combined cell and gene therapy for genodermatoses","volume":"12","author":"De Rosa","year":"2020","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng0395-279","article-title":"Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis","volume":"9","author":"Russell","year":"1995","journal-title":"Nat. Genet."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1083\/jcb.103.4.1577","article-title":"Type VII collagen is a major structural component of anchoring fibrils","volume":"103","author":"Sakai","year":"1986","journal-title":"J. Cell Biol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1073\/pnas.0800940105","article-title":"Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases","volume":"105","author":"Santiago","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B150","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40291-016-0243-y","article-title":"Netherton syndrome: a genotype-phenotype review","volume":"21","author":"Sarri","year":"2017","journal-title":"Mol. Diagn Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"112019","DOI":"10.1016\/j.celrep.2023.112019","article-title":"Modulating mutational outcomes and improving precise gene editing at CRISPR-Cas9-induced breaks by chemical inhibition of end-joining pathways","volume":"42","author":"Schimmel","year":"2023","journal-title":"Cell Rep."},{"key":"B152","doi-asserted-by":"publisher","first-page":"101311","DOI":"10.1016\/j.omtm.2024.101311","article-title":"A cellular disease model toward gene therapy of TGM1-dependent lamellar ichthyosis","volume":"32","author":"Sercia","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B153","doi-asserted-by":"publisher","first-page":"19643","DOI":"10.1038\/s41598-022-24184-8","article-title":"ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation","volume":"12","author":"Sheriff","year":"2022","journal-title":"Sci. Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa","volume":"113","author":"Shinkuma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B155","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4274\/tjod.63004","article-title":"Harlequin ichthyosis: a rare case","volume":"14","author":"Shruthi","year":"2017","journal-title":"Turk J. Obstet. Gynecol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"B157","article-title":"Epidermolysis Bullosa simplex","volume-title":"Genereviews\u00ae","author":"So","year":"1993"},{"key":"B158","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","article-title":"Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa","volume":"17","author":"So","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1016\/j.jid.2024.04.013","article-title":"Twin prime editing mediated exon skipping\/reinsertion for restored collagen VII expression in recessive dystrophic epidermolysis bullosa","volume":"144","author":"Steinbeck","year":"2024","journal-title":"J. Invest Dermatol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jid.2019.02.015","article-title":"Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR\/Cas9","volume":"139","author":"Takashima","year":"2019","journal-title":"J. Invest Dermatol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.7150\/thno.125705","article-title":"Harnessing nucleotide metabolism to control glycosylase base editing outcomes","volume":"16","author":"Tao","year":"2026","journal-title":"Theranostics"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/mt.2010.91","article-title":"SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa","volume":"18","author":"Titeux","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/gt.2016.57","article-title":"Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations","volume":"23","author":"Tockner","year":"2016","journal-title":"Gene Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B167","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-1-61779-767-5_15","article-title":"Antisense-mediated exon skipping to reframe transcripts","volume":"867","author":"Turczynski","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"B169","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-017-0313-x","article-title":"Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment","volume":"19","author":"Vahlquist","year":"2018","journal-title":"Am. J. Clin. Dermatol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jmg.2006.045302","article-title":"Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes","volume":"44","author":"Varki","year":"2007","journal-title":"J. Med. Genet."},{"key":"B171","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.3390\/ijms222212222","article-title":"Therapeutic prospects of exon skipping for epidermolysis Bullosa","volume":"22","author":"Vermeer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B172","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5070\/D34NT615VJ","article-title":"Lamellar ichthyosis","volume":"11","author":"Victor","year":"2005","journal-title":"Dermatol Online J."},{"key":"B173","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.mrrev.2024.108515","article-title":"Advances in base editing: a focus on base transversions","volume":"794","author":"Wang","year":"2024","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"B174","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/npjregenmed.2016.14","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa","volume":"1","author":"Webber","year":"2016","journal-title":"NPJ Regen. Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s13555-021-00561-5","article-title":"Clinical perspectives of gene-targeted therapies for epidermolysis Bullosa","volume":"11","author":"Welponer","year":"2021","journal-title":"Dermatol Ther."},{"key":"B176","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1038\/s41467-025-65182-4","article-title":"Unveiling the cut-and-repair cycle of designer nucleases in human stem and T cells via CLEAR-time dPCR","volume":"16","author":"White","year":"2025","journal-title":"Nat. Commun."},{"key":"B177","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1038\/s41467-023-40344-4","article-title":"Simultaneous inhibition of DNA-PK and Pol\u03f4 improves integration efficiency and precision of genome editing","volume":"14","author":"Wimberger","year":"2023","journal-title":"Nat. Commun."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J. Invest Dermatol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","author":"Woodley","year":"2004","journal-title":"Nat. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","author":"Woodley","year":"2013","journal-title":"J. Invest Dermatol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0305-4179(95)90774-t","article-title":"An investigation into the mechanisms by which human dermis does not significantly contribute to the rejection of allo-skin grafts","volume":"21","author":"Wu","year":"1995","journal-title":"Burns J. Int. Soc. Burn Inj."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1186\/s12967-024-05957-3","article-title":"From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ymthe.2005.09.006","article-title":"Spliceosome-mediated RNA trans-splicing","volume":"12","author":"Yang","year":"2005","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B185","doi-asserted-by":"publisher","first-page":"113842","DOI":"10.1016\/j.addr.2021.113842","article-title":"Highly branched poly(\u03b2-amino ester)s for gene delivery in hereditary skin diseases","volume":"176","author":"Zeng","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.tibtech.2023.03.004","article-title":"Prime editing: advances and therapeutic applications","volume":"41","author":"Zhao","year":"2023","journal-title":"Trends Biotechnol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jconrel.2016.06.014","article-title":"Highly branched poly(\u03b2-amino ester)s for skin gene therapy","volume":"244","author":"Zhou","year":"2016","journal-title":"J. Control. Release"}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1901459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:31:13Z","timestamp":1787549473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1901459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":186,"alternative-id":["10.3389\/fbioe.2026.1901459"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1901459","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1901459"}}